A Randomized,Single-Blind,Substitution Study of OROS Methylphenidate (Concerta) in ADHD Adults Receiving Immediate Release Methylphenidate

Abstract

Objective: The main aim of this study was to examine the efficacy, tolerability, and compliance of an extended-release formulation of methylphenidate (OROS-MPH) in adults with ADHD receiving immediate-release methylphenidate (IR-MPH). Method: Participants were outpatient adults with ADHD who were stable on IR-MPH-administered TID. Participants were randomized (4:1) to equipotent doses of OROS-MPH or to continue IR-MPH and were assessed weekly for 6 weeks with the Adult ADHD Investigator System Symptom Report Scale (AISRS). Results: Randomization of 53 IR-MPH responders to IR- or OROS-MPH had no effect on AISRS score at endpoint (11.2 ± 6.9 vs. 10.7 ± 5.1, p = .8). Participants stabilized on IR-MPH and switched to OROS-MPH remained satisfied over 71% of the time. However, the IR-MPH group missed more doses (7.3 ± 6.8 vs. 3.3 ± 4.2, p = .02) than the OROS-MPH group. Conclusion: Findings showed that adults with ADHD can be successfully switched from an effective regimen of IR-MPH TID to once-daily OROS-MPH. Results also demonstrated better compliance with OROS-MPH than with IR-MPH treatment. (J. of Att. Dis. 2011; 15(4) 286-294)

Keywords

ADHD adult clinical trial methylphenidate

Get full access to this article

View all access options for this article.

References

American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author .

Biederman, J. ( 2006). Comparative and acute efficacy and tolerability of OROS and iommmediate release formulations of methylphenidate in the treatment of adults with attention deficit hyperactivity disorder. Biological Psychiatry, 59(Suppl. 8), 115S.

Biederman, J. , Faraone, S.V. , Spencer, T. , Wilens, T. , Norman, D. , Lapey, K.A. , . . . Doyle, A. ( 1993). Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry, 150, 1792-1798.

Biederman, J. , Mick, E. , Surman, C. , Doyle, R. , Hammerness, P. , Harpold, T. , . . . Spencer, T. ( 2006). A randomized, placebo-controlled trial of OROS-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 59, 829-835.

First, M.B. , Spitzer, R.L. , Gibbon, M. , & Williams, J.B.W. (1997). Structured clinical interview for DSM-IV Axis I disorders-clinician version (SCID-CV). Washington, DC: American Psychiatric Press.

Greenhill, L. , Beyer D.H. , Finkleson, J. , Shaffer, D. , Biederman, J. , Conners, C.K. , . . . Volkow, N. ( 2002). Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder. Journal of Attention Disorders, 6(Supp. 1), 89-100.

Hamilton, M. ( 1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50-55.

Hamilton, M. ( 1960). A rating scale for depression. Journal of Neurological and Neurosurgical Psychiatry, 23, 56-62.

National Institute of Mental Health. (1985 ). CGI (Clinical Global Impression) Scale-NIMH. Psychopharmacology Bulletin, 21, 839-844.

10.

Orvaschel, H. ( 1994). Schedule for affective disorder and schizophrenia for school-age children epidemiologic version (5th ed.). Ft. Lauderdale, FL: Nova Southeastern University.

11.

Pelham, W.E. , Gnagy, E.M. , Burrows-Maclean, L. , Williams, A. , Fabiano, G.A. , Morrisey, S.M. , . . . Morse, G.D. ( 2001). Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics , 107, E105.

12.

Spencer, T. , & Adler, L. ( 2004). Diagnostic approaches to adult attention-deficit/hyperactivity disorder. Primary Psychiatry, 11, 49-53.

13.

Spencer, T. , Biederman, J. , Wilens, T. , Doyle, R. , Surman, C. , Prince, J. , . . . Faraone, S. ( 2005). A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 57, 456-463.

14.

Spencer, T. , Biederman, J. , Wilens, T. , & Faraone, S.V. ( 1994). Is attention deficit hyperactivity disorder in adults a valid disorder? Harvard Review of Psychiatry, 1, 326-335.

15.

Spencer, T.J. , Biederman, J. , Ciccone, P.E. , Madras, B.K. , Dougherty, D.D. , Bonab, A.A. , . . . Fischman, A.J. (2006). A PET study examining pharmacokinetics, detection and like-ability, and dopamine transporter receptor occupancy of short and long-acting orally administered formulations of methylphenidate in adults. American Journal of Psychiatry, 163, 387-395.

16.

Swanson, J. , Greenhill, L. , Pelham, W. , Wilens, T. , Wolraich, M. , Abikoff, H. , . . . . Winans, E. ( 2000). Initiating Concerta (OROS methylphenidate HCl) qd in children with attention-deficit hyperactivity disorder. Journal of Clinical Research, 3, 59-76.

17.

Volkow, N.D. , & Swanson, J.M. ( 2003). Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. American Journal of Psychiatry, 160, 1909-1918.

18.

Wolraich, M.L. , Greenhill, L.L. , Pelham, W. , Swanson, J. , Wilens, T. , Palumbo, D. , . . . August, G. ( 2001). Randomized controlled trial of OROS Methylphenidate qd in children with attention deficit/hyperactivity disorder. Pediatrics, 108, 883-892.